Neodolpasse (Diclofenac Sodium, Orphenadrine Citrate)

Diclofenac Sodium and Orphenadrine Citrate, the active ingredients in Neodolpasse, are a non‑steroidal anti‑inflammatory drug and a centrally acting muscle relaxant presented as an intravenous formulation for hospital use. They are employed to relieve pain, reduce inflammation, and alleviate skeletal muscle spasm in adult patients. It is commonly used in acute postoperative settings.

GNH USA supplies Neodolpasse as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Neodolpasse combines an NSAID and a muscle relaxant, acting on inflammatory pathways and skeletal muscle spasm.

- Pain: Provides analgesic relief by reducing inflammatory mediators and decreasing muscle tension. - Inflammation: Decreases prostaglandin synthesis to control swelling in acute musculoskeletal conditions. - Muscle spasm: Relieves skeletal muscle spasm through central anticholinergic activity, improving mobility.

Neodolpasse may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: Mild gastrointestinal upset occurring in some patients. - Headache: Transient headache reported after infusion. - Dizziness: Light‑headed sensation that usually resolves quickly. - Injection site pain: Local discomfort at the site of administration. - Flushing: Warmth and reddening of the skin. - Dry mouth: Reduced salivation during therapy.

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding: Potential for serious bleeding in the stomach or intestines. - Hepatic enzyme elevation: Possible liver function abnormalities requiring monitoring. - Renal impairment: Decreased kidney function, especially in at‑risk patients. - Severe allergic reactions (anaphylaxis): Rapid onset of rash, swelling, and respiratory distress. - Cardiac arrhythmia: Irregular heart rhythm in susceptible individuals. - Neutropenia: Low white‑blood‑cell count that can increase infection risk.

Before initiating Neodolpasse, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

- Renal function: Assess baseline renal function and monitor during therapy. - Hepatic function: Avoid in patients with severe liver disease or monitor liver enzymes closely. - Cardiovascular risk: Use cautiously in patients with a history of myocardial infarction or stroke. - Bleeding risk: Avoid concomitant use with anticoagulants unless medically necessary. - Pregnancy and lactation: Use only if benefits outweigh risks; consult a specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Neodolpasse can interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Lithium: diclofenac may raise lithium serum concentrations. - MAO inhibitors: risk of hypertensive crisis when combined with orphenadrine.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal function when used together. - Diuretics: potential for enhanced renal impairment. - Corticosteroids: increased risk of gastrointestinal ulceration.